Metraipolis › archive › dc_c43ffbb38048

Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER):… — Europe PMC PMID:41213939

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41213939
DOI
10.1038/s41392-[numero omesso]-z
License (as archived)
solo-consultazione
Archived
2026-11-08T16:22:54.844Z
SHA-256 of the archived text
15a375bcc77c1496c457bd3fba8a87deafc71b43abff43376bd56758740e826b
Stable URL of this page
https://metraipolis.com/documento/dc_c43ffbb38048

How to cite

Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER):… — Europe PMC PMID:41213939 — Europe PMC (en), https://europepmc.org/article/MED/41213939 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c43ffbb38048 (Metraipolis archive dc_c43ffbb38048, sha256 15a375bcc77c1496c457bd3fba8a87deafc71b43abff43376bd56758740e826b)
BibTeX
@misc{dcc43ffbb38048,
  title = {Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER):… — Europe PMC PMID:41213939},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41213939},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c43ffbb38048; sha256 15a375bcc77c1496c457bd3fba8a87deafc71b43abff43376bd56758740e826b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41213939. Agents can read the archived copy with the MCP tool read_document.